|
|
|
|
|
|
|
|
|
|
Conclusions:
These data suggest that bevacizumab did not increase the risk of severe bleeding in cancer patients who received
Friday, January 21, 2011
abstract: Bleeding events in (Avastin) bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
Conclusions:
These data suggest that bevacizumab did not increase the risk of severe bleeding in cancer patients who received
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.